Lincoln, Nebraska, May 25, 2023 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ:NRC) today announced that its Board of Directors has declared a quarterly cash dividend of $0.12 (twelve cents) per share payable Friday, July 14, 2023, to shareholders of record as of the close of business on Friday, June 30, 2023.
For more than 40 years, NRC Health has been committed to achieving Human Understanding and bringing healthcare organizations closer to their customers than ever before by illuminating and improving the key moments that define an experience and build trust. Guided by their uniquely empathic heritage, proprietary methods, skilled associates, and holistic approach, NRC Health helps its customers design experiences that exceed expectations, inspire loyalty, and improve well-being among patients, residents, physicians, nurses, and staff.
| Last Trade: | US$14.91 |
| Daily Change: | -0.04 -0.27 |
| Daily Volume: | 95,383 |
| Market Cap: | US$339.800M |
April 28, 2025 February 25, 2025 January 27, 2025 October 25, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
